Bubs' growth strategy boosted by FDA approval
About this video
Key points
Bubs secures permanent FDA approval for three US infant formulas
US growth strategy shifts from regulatory approval to driving store sales
Private label offers another avenue for long-term US expansion
Bubs Australia has secured permanent US FDA authorisation for three infant formula lines, removing a major regulatory hurdle after four years of work. CEO Joe Coote says the milestone provides a platform to accelerate the company's US growth strategy, deepen retailer partnerships and expand its consumer reach.
With Bubs now available in more than 10,000 US stores across all 50 states, the focus shifts towards increasing sales and throughput across its existing retail footprint. Coote says the company sees significant runway in the large US premium natural infant formula market, with its goat formula already its biggest-selling product and Australian provenance helping differentiate the brand.
The FDA approval also creates new optionality for Bubs, including potential entry into the US private-label infant nutrition market. Coote says that opportunity will require further regulatory, technical and commercial work, while the company also works through previous cost pressures and the impact of US tariffs.